Precigen, Inc. (NASDAQ:PGEN) has been given an average rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $9.25.
A number of research firms have recently issued reports on PGEN. Zacks Investment Research cut shares of Precigen from a “buy” rating to a “hold” rating in a research report on Thursday, May 28th. ValuEngine raised shares of Precigen from a “hold” rating to a “buy” rating in a research report on Friday, May 1st. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Precigen in a research report on Wednesday, June 24th. Finally, JMP Securities reissued an “outperform” rating and set a $13.00 price objective on shares of Precigen in a research report on Wednesday, June 10th.
In related news, CFO Rick L. Sterling sold 7,619 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $4.50, for a total value of $34,285.50. Following the transaction, the chief financial officer now owns 295,592 shares of the company’s stock, valued at approximately $1,330,164. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Donald P. Lehr sold 8,428 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $4.50, for a total transaction of $37,926.00. Following the completion of the transaction, the insider now directly owns 239,986 shares in the company, valued at approximately $1,079,937. The disclosure for this sale can be found here. 50.70% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Third Security LLC purchased a new stake in Precigen in the 1st quarter valued at about $281,488,000. BlackRock Inc. purchased a new stake in Precigen in the 1st quarter valued at about $23,142,000. State Street Corp purchased a new stake in Precigen in the 1st quarter valued at about $12,693,000. Nikko Asset Management Americas Inc. purchased a new stake in Precigen in the 1st quarter valued at about $9,361,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in Precigen in the 1st quarter valued at about $9,361,000. Hedge funds and other institutional investors own 75.71% of the company’s stock.
PGEN traded down $0.05 during trading on Friday, reaching $4.88. 16,830 shares of the stock traded hands, compared to its average volume of 4,076,835. The company has a quick ratio of 2.47, a current ratio of 2.68 and a debt-to-equity ratio of 2.42. The stock has a market capitalization of $840.29 million, a PE ratio of -2.41 and a beta of 1.55. The stock’s 50-day moving average is $3.48 and its 200 day moving average is $3.61. Precigen has a 12 month low of $1.26 and a 12 month high of $8.70.
Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.19) EPS for the quarter. The firm had revenue of $29.84 million for the quarter. Precigen had a negative net margin of 300.01% and a negative return on equity of 81.74%. As a group, equities research analysts anticipate that Precigen will post -0.68 EPS for the current year.
Precigen Company Profile
Precigen, Inc engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies.
Further Reading: Why are percentage gainers important?
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.